LCT 0.01
9 January 2022
Application for quotation of securities
Securities issued as part of transactions previously announced.
9 January 2022
Update to application for quotation of securities
Update to previous announcement.
24 January 2022
LCT signs Service Agreement with NZeno, secures pig cells for NTCELL trial
31 January 2022
Quarterly Activities Report/Appendix 4C - December Quarter 2021
25 February 2022
Half Yearly Report and Accounts
The half-year to 31 December 2021 saw further advances concerning the company’s plans for a third clinical trial of NTCELL in Parkinson’s disease, a disease affecting more than 10 million people worldwide.